Stocktwits on MSN
RGNX shares pare losses as Wall Street dismisses gene therapy clinical hold spurred selloff as an overreaction
Leerink said the premarket selloff in shares underscores the degree of surprise on the news, feeding into the "FDA ...
REGENXBIO (RGNX) lost ~35% in the premarket on Wednesday after the company said that the U.S. Food and Drug Administration ...
REGENXBIO shares sink after the FDA places a clinical hold on two gene therapy trials following a safety concern tied to ...
Jan 28 (Reuters) - Regenxbio said on Wednesday the U.S. Food and Drug Administration has placed a clinical hold on two of its ...
Regenxbio Inc. faces pivotal catalysts in 2026, notably RGX-121's FDA decision and RGX-202 Duchenne data, potentially ...
Investing.com -- REGENXBIO Inc. (NASDAQ:RGNX) stock fell 28% Wednesday after the FDA placed clinical holds on two of its ...
As of Wednesday, January 28, REGENXBIO Inc.’s RGNX share price has dipped by 18.49%, which has investors questioning if this is right time to buy.
REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its ...
Regenxbio (RGNX) came out with a quarterly loss of $1.2 per share versus the Zacks Consensus Estimate of a loss of $1.38. This compares to a loss of $1.17 per share a year ago. These figures are ...
Regenxbio (RGNX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to loss of $1.38 per share a year ago. These figures are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results